On 2 May 2024, Celltrion announced that it has won a 12 month tender to supply Remsima®, biosimilar to Janssen’s Remicade® (infliximab) and Herzuma®, biosimilar to Roche’s Herceptin® (trastuzumab), in Peru. Celltrion expects to capture 86% of Peru’s infliximab market and 50% of Peru’s trastuzumab market. Remicade® will be supplied from the end of May while Herzuma® will be supplied from July 2024.
This follows Celltrion’s recent tender successes regarding Remsima SC® in Denmark(April 2024), Norway (February 2024), and Sicily (January 2024). In February 2024, Celltrion also secured a series of tenders in Peru to supply Herzuma® (trastuzumab biosimilar), Truxima® (rituximab biosimilar) and Yuflyma® (adalimumab biosimilar). These contracts effectively secured more than 50% of the Peruvian rituximab and trastuzumab markets, and an estimated 20% of the Peruvian adalimumab market.